Literature DB >> 19247033

Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer.

Jeon-Hor Chen1, Byron A Feig, David J-B Hsiang, John A Butler, Rita S Mehta, Shadfar Bahri, Orhan Nalcioglu, Min-Ying Su.   

Abstract

OBJECTIVE: To investigate how MRI imaging of neoadjuvant chemotherapy (NAC) tumor response affects the recommendation for optimal breast cancer surgery, both before and after NAC. SUMMARY BACKGROUND DATA: Understanding how imaging findings are incorporated into surgeons' decision-making processes will help establish appropriate imaging guidelines for recommending breast conservation surgery (BCS) after the NAC.
METHODS: Seventy-six breast cancer patients undergoing NAC with MRI follow-up studies were analyzed. Two experienced breast surgeons reviewed all cases. An initial surgical recommendation was made based on the pre-NAC lesion presentation; a subsequent surgical recommendation was made based on the post-NAC tumor response. Finally, the pathology results were disclosed and the surgeons were asked to decide on the optimal definitive surgical procedure. MRI findings throughout the entire course of the NAC were analyzed to understand how they affected different recommendations.
RESULTS: Before the NAC, a large tumor size or extent of disease were the primary determinant factors for mastectomy. In this study, the mean tumor size was 5.3 +/- 3.4 cm (RECIST) in the mastectomy group and 3.2 +/- 1.6 cm in the lumpectomy group (P = 0.0001). After the NAC, based on consensus recommendations, 21 mastectomy candidates remained for mastectomy, with tumor size decreasing from 7.4 +/- 4.5 to 1.5 +/- 2.5 cm, and 22 mastectomy candidates were changed to lumpectomy, with tumor size decreasing from 4.2 +/- 2.1 to 0.4 +/- 0.6 cm. When the final pathology revealed pCR or minimal residual disease, the surgeons agreed that BCS is the optimal procedure. On the other hand, for a large extent of residual disease, mastectomy should be performed.
CONCLUSION: In patients who had more extensive pretreatment disease, despite an excellent response to NAC, the surgeons still tended to apply an aggressive approach and recommended mastectomy. Given that the confirmation of pCR or minimal residual disease would change surgeons' recommendations for less aggressive, conservation surgery, the maturity of MRI for NAC response prediction may provide reliable staging information to aid in the recommendation of the optimal surgical procedure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247033      PMCID: PMC2789298          DOI: 10.1097/SLA.0b013e31819a6e01

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  42 in total

1.  Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.

Authors:  Sibylle Loibl; Gunter von Minckwitz; Günther Raab; Jens-Uwe Blohmer; Serban Dan Costa; Bernd Gerber; Holger Eidtmann; Simone Petrich; Jörn Hilfrich; Christian Jackisch; Andreas du Bois; Manfred Kaufmann
Journal:  Ann Surg Oncol       Date:  2006-09-17       Impact factor: 5.344

Review 2.  Neoadjuvant chemotherapy for operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

3.  Breast conservation after neoadjuvant chemotherapy.

Authors:  Siegal Sadetzki; Bernice Oberman; Douglas Zipple; Bella Kaufman; Shulamit Rizel; Ilya Novikov; Moshe Z Papa
Journal:  Ann Surg Oncol       Date:  2005-04-19       Impact factor: 5.344

4.  MRI and conservative treatment of locally advanced breast cancer.

Authors:  T Julius; S E G Kemp; P J Kneeshaw; A Chaturvedi; P J Drew; L W Turnbull
Journal:  Eur J Surg Oncol       Date:  2005-12       Impact factor: 4.424

5.  Conservation surgery for breast cancer as the preferred choice: a prospective analysis.

Authors:  Walley J Temple; Margaret L Russell; Louise L Parsons; Sylvia M Huber; Charlotte A Jones; Jane Bankes; Michael Eliasziw
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

6.  Predictors of breast conservation therapy: size is not all that matters.

Authors:  Karen Hiotis; Wei Ye; Richard Sposto; Kristin A Skinner
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

7.  Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy.

Authors:  Julia L Oh; Mark J Dryden; Wendy A Woodward; Tse-Kuan Yu; Welela Tereffe; Eric A Strom; George H Perkins; Lavinia Middleton; Kelly K Hunt; Sharon H Giordano; Mary Jane Oswald; Delora Domain; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.

Authors:  Maria Bodini; Alfredo Berruti; Alberto Bottini; Giovanni Allevi; Carla Fiorentino; Maria Pia Brizzi; Alessandra Bersiga; Daniele Generali; Davide Volpi; Ugo Marini; Sergio Aguggini; Marco Tampellini; Palmiro Alquati; Lucio Olivetti; Luigi Dogliotti
Journal:  Breast Cancer Res Treat       Date:  2004-06       Impact factor: 4.872

9.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

Authors:  Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

View more
  14 in total

1.  Characterizing accuracy of total hemoglobin recovery using contrast-detail analysis in 3D image-guided near infrared spectroscopy with the boundary element method.

Authors:  Hamid R Ghadyani; Subhadra Srinivasan; Brian W Pogue; Keith D Paulsen
Journal:  Opt Express       Date:  2010-07-19       Impact factor: 3.894

2.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.

Authors:  Albert E Cerussi; Vaya W Tanamai; David Hsiang; John Butler; Rita S Mehta; Bruce J Tromberg
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

3.  Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.

Authors:  Darren Roblyer; Shigeto Ueda; Albert Cerussi; Wendy Tanamai; Amanda Durkin; Rita Mehta; David Hsiang; John A Butler; Christine McLaren; Wen-Pin Chen; Bruce Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

Review 4.  MRI in breast cancer therapy monitoring.

Authors:  Rebekah McLaughlin; Nola Hylton
Journal:  NMR Biomed       Date:  2011-06-21       Impact factor: 4.044

5.  Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer.

Authors:  L Corke; L Luzhna; K Willemsma; C Illmann; M Mcdermott; C Wilson; C Simmons; N LeVasseur
Journal:  Breast Cancer Res Treat       Date:  2022-06-15       Impact factor: 4.624

6.  Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Christine E McLaren; Wen-Pin Chen; Peter T Fwu; David J B Hsiang; Karen T Lane; John A Butler; Min-Ying Su
Journal:  J Surg Oncol       Date:  2013-10-28       Impact factor: 3.454

7.  Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

Authors:  Claudette E Loo; Lisanne S Rigter; Kenneth E Pengel; Jelle Wesseling; Sjoerd Rodenhuis; Marie-Jeanne T F D Vrancken Peeters; Karolina Sikorska; Kenneth G A Gilhuijs
Journal:  Breast Cancer Res       Date:  2016-08-05       Impact factor: 6.466

8.  Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?

Authors:  Rebecca Leddy; Abid Irshad; Lara Hewett; Heather Collins; Frank Vento; Susan Ackerman; Madelene Lewis
Journal:  J Clin Imaging Sci       Date:  2016-09-20

Review 9.  Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Jeon-Hor Chen; Min-Ying Su
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

10.  Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2013-06-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.